Spring River Plumbing CXO Prophet

Investment and financing data is a stone
to suppress biomedicine.

According to Arterial Network, in November 2022, a total of 28 financing events occurred in the domestic biomedical field, with a total financing of US$587 million, an increase of about 232%
from the previous month.
According to CaiLian Venture Capital Connect, in November 2022, a total of 140 private equity investment and financing events occurred in the statistics of the domestic medical and health field, an increase of 119% month-on-month, and the total disclosed financing was about 5.
199 billion yuan, an increase of 12% month-on-month.

The recovery of investment and financing in a single month may not yet have directional significance, but splitting specific cases will find that the quality of investment and financing is more important
than quantity.

We have an in-depth analysis of the 31 representative next-generation biotechs that will raise new funding rounds in the second half of 2022 (November 21, "Will the Next Generation of Innovative Pharmaceutical Companies Let Us Down?").
), to verify the great role of market regulation, innovative pharmaceutical companies established since 2020, pipelines and technical directions to avoid homogenization with predecessors as much as possible, have been to the greatest extent to the forefront and differentiation, involving synthetic lethality, CAR-NK and TCR-T cell therapy, gene therapy, new generation of monoclonal and bispecific antibodies, next-generation protein-degrading drugs, new conjugate drugs
.

Next-generation Biotech, which was newly financed in December, continues to explore
new molecular species.
Westin Biologics, established in 2021, raised 150 million yuan in Series A financing, and 4 drug candidates entered the clinical trial stage, including mRNA vaccines with new coronavirus variants, mRNA drugs for the treatment of EBV-related tumors, mRNA drugs for the treatment of liver cancer, and WGa01
, a new adjuvant.
Sprout Gene, established in 2020, raised tens of millions of dollars in Series A financing to use base editing technology for gene therapy drug research and development
.
Founded in June 2022, Contingent Biologics raised US$15 million in seed rounds and has established a unique drug discovery platform
for targets related to protein translation regulation.

In response to new changes in the biotechnology industry, WuXi is prospectively executing its "follow and win the molecule" strategy
.

You should never doubt the determination of Chinese-American Li Ge to reduce his holdings and leave, or WuXi's ability to see into the future, the two can be completely separated, and the founder's behavior no longer affects the company's operations
.

In the first three quarters of this year, WuXi AppTec's capacity building for new molecular classes ran through all business segments
.
In the chemical business, revenue from the new molecule related business increased year-over-year 192.
5%, the number of D&M service customers for oligonucleotide and peptide drugs reached 97, a year-on-year increase of 98%, the number of molecules served reached 155, a year-on-year increase of 101%, and service revenue reached 1.
1 billion yuan, a year-on-year increase of 406%.

July 2022 In January, another new oligonucleotide and peptide production building at the Changzhou base was officially put into operation, further enhancing large-scale production capacity, and the aseptic lipid nanoparticle preparation platform in the Wuxi base was put into operation
.
In the biology business, involving targeted protein degradation, new nucleic acid molecules, conjugated new molecules, oncolytic viruses, vector platforms, and innovative drug delivery systems, the revenue related to new molecular types and biological drugs increased by 76% year-on-year, and the proportion of revenue in the biology business increased to 20.
5%.

CGT business, providing development and manufacturing services for 67 cell and gene therapy programs, including 8 III Phase clinical trial projects (4 projects in the preparation stage of marketing application).

AAV produced by TESSA™ technology released this year More than 10x based on plasmid methods are produced, and 38 related projects are currently being evaluated by customers
.

WuXi AppTec's DDSU (Domestic New Drug R&D) business is an important window to observe the trend of domestic innovative drugs, and revenue in the first three quarters of this year fell by 27.
9% year-on-year, reflecting the pain
of homogenization capacity clearance.
Positive change is what the company is carrying out for its customers 15 new molecule classes preclinical programs, including peptides/peptide drug conjugates (PDCs),

Protein degraders and oligonucleotides, several of which will submit IND applications
in late 2022 or early 2023.

Small molecule CDMOs are evolving, no longer static concepts
as you understand them.
Kailaiying and Porton are also expanding new molecular types of business and looking for new impetus in incremental space, which can also be regarded as an effort
by CDMO to avoid overcapacity.

In the first three quarters of this year, the revenue of emerging business was 671 million yuan, a year-on-year increase of 154%, and the orders in hand were about
1.
5 billion yuan.
At the end of this year, a 12,000-square-meter R&D center exclusive to chemical macromolecules was built 9500 square meters GMP workshop
.
The synthetic biotechnology R&D center and production workshop will also be completed by the end of this year

Enabled
.
The production capacity of biological macromolecules is about to enter the release period, and 2022H1 has completed the construction of 2x2000L disposable bioreactor antibody stock solution production capacity; 100L ADC The coupling stock pilot plant has been put into use, and the 2x500L ADC commercial coupling stock production capacity was put into use at the end of September; Suzhou plasmid, mRNA business pilot capacity

It has been put into production and has the service capabilities
of IND and clinical sample preparation.

On December 21, the CDMO industrialization base of Boton Biotech was officially launched, with a total area of more than 20,000 square meters of gene and cell therapy process development and production workshops, 10 GMP virus vector production lines, 12 GMP cell therapy production lines (including 2 positive production workshops) and hundreds of clean workshops, CGT therapy will gradually achieve large-scale commercial production
.

02 The pace of the head company